Relevant bibliographies by topics / Enzalutamide resistance

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Enzalutamide resistance'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Enzalutamide resistance.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Enzalutamide resistance"

1

Prekovic, S., T. Van den Broeck, S. Linder, et al. "Molecular underpinnings of enzalutamide resistance." Endocrine-Related Cancer 25, no. 11 (2018): R545—R557. http://dx.doi.org/10.1530/erc-17-0136.

Full text
Abstract:
Prostate cancer (PCa) is among the most common adult malignancies, and the second leading cause of cancer-related death in men. As PCa is hormone dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease. The discovery of enzalutamide, a compound that effectively blocks the AR axis and its clinical application has led to a significant improvement in survival time. However, the effect of enzalutamide is not permanent, and resistance to treatment ultimately leads to development of lethal disease, for which there curr
APA, Harvard, Vancouver, ISO, and other styles
2

Thoma, Clemens. "Fitting to overcome enzalutamide resistance." Nature Reviews Urology 13, no. 10 (2016): 564–65. http://dx.doi.org/10.1038/nrurol.2016.160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bai, Yunfeng, Zhuangzhuang Zhang, Lijun Cheng, et al. "Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer." Journal of Biological Chemistry 294, no. 25 (2019): 9911–23. http://dx.doi.org/10.1074/jbc.ra119.008152.

Full text
Abstract:
Enzalutamide, approved by the United States Food and Drug Administration in 2018 for the management of metastatic castration-resistant prostate cancer (CRPC), is an androgen receptor (AR) inhibitor. It blocks androgen binding to the AR, AR nuclear translocation, and AR-mediated DNA binding. Unfortunately, a considerable proportion of tumors eventually develop resistance during the treatment. The molecular mechanisms underlying enzalutamide resistance are not completely understood. Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressor complex 2, has been proposed as a
APA, Harvard, Vancouver, ISO, and other styles
4

Sharifi, Nima, Jianneng Li, Mohammad Alyamani, et al. "Aberrant tumor metabolism to enable glucocorticoid receptor takeover in enzalutamide-resistant prostate cancer." Journal of Clinical Oncology 35, no. 6_suppl (2017): 157. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.157.

Full text
Abstract:
157 Background: Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs progression-free and overall survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimulating expression of approximately 50% of genes normally stimulated by AR, thereby permitting continued growth despite AR blockade. However, countering this mechanism by administration of GR antagonists is problematic because GR is essential for life. Met
APA, Harvard, Vancouver, ISO, and other styles
5

Feng, Tao, Dechao Wei, Jiahui Zhao, et al. "Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes." Experimental Biology and Medicine 246, no. 15 (2021): 1776–87. http://dx.doi.org/10.1177/15353702211012625.

Full text
Abstract:
Among many factors of causing castration-resistant prostate cancer (CRPC) progression, a growing number of evidences have shown androgen receptors play a critical role. Therefore, blocking androgen receptor remains a therapeutic goal of CRPC. However, resistance to androgen receptor inhibitors, for example, enzalutamide, limits therapeutic efficacy for many patients. In this study, to develop an enzalutamide-resistant cell model for molecular mechanism investigation of enzalutamide-resistance, we continuously treated C4-2B cells with multiplied concentrations of enzalutamide. The IC50 of resis
APA, Harvard, Vancouver, ISO, and other styles
6

Chia, KeeMing, Heloisa Milioli, Neil Portman, et al. "Non-canonical AR activity facilitates endocrine resistance in breast cancer." Endocrine-Related Cancer 26, no. 2 (2019): 251–64. http://dx.doi.org/10.1530/erc-18-0333.

Full text
Abstract:
The role of androgen receptor (AR) in endocrine-resistant breast cancer is controversial and clinical trials targeting AR with an AR antagonist (e.g., enzalutamide) have been initiated. Here, we investigated the consequence of AR antagonism using in vitro and in vivo models of endocrine resistance. AR antagonism in MCF7-derived tamoxifen-resistant (TamR) and long-term estrogen-deprived breast cancer cell lines were achieved using siRNA-mediated knockdown or pharmacological inhibition with enzalutamide. The efficacy of enzalutamide was further assessed in vivo in an estrogen-independent endocri
APA, Harvard, Vancouver, ISO, and other styles
7

Chen, Xuedong, Jieyang Lu, Liqun Xia, and Gonghui Li. "Drug Resistance of Enzalutamide in CRPC." Current Drug Targets 19, no. 6 (2018): 613–20. http://dx.doi.org/10.2174/1389450118666170417144250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Stone, Louise. "Escaping enzalutamide: Malat1 contributes to resistance." Nature Reviews Urology 14, no. 8 (2017): 450. http://dx.doi.org/10.1038/nrurol.2017.91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fenner, Annette. "Enzalutamide—differential cross resistance with taxanes." Nature Reviews Urology 12, no. 2 (2014): 64. http://dx.doi.org/10.1038/nrurol.2014.353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lee, Hsiu-Chi, Chien-Hui Ou, Yun-Chen Huang, et al. "YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer." Oncogene 40, no. 13 (2021): 2407–21. http://dx.doi.org/10.1038/s41388-021-01718-4.

Full text
Abstract:
AbstractMetastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy. Since enzalutamide is innovated and approved by US FDA as a new treatment option for mCRPC patients, drug resistance for enzalutamide is a critical issue during clinical usage. Although several underlying mechanisms causing enzalutamide resistance were previously identified, most of them revealed that drug resistant cells are still highly addicted to androgen and AR functions. Due to the numerous physical functions of AR in men, innovated
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Enzalutamide resistance"

1

Alsamraae, Massar Ibrahim Shekhan. "Investigating aberrant signalling in enzalutamide-resistant prostate cancer." Thesis, University of Newcastle upon Tyne, 2017. http://hdl.handle.net/10443/3961.

Full text
Abstract:
Prostate cancer is usually androgen-dependent and consequently, initial therapy for many patients, particularly with advanced disease, is androgen withdrawal, via anti-androgen therapeutics. Most patients respond to anti-androgen therapy in the early stages of their disease but many will develop resistance, entering a “castrate-resistant” disease state. Enzalutamide and ARN-509 have shown promise in the treatment of castration resistant prostate cancer (CRPC) patients, however response rates are just 50% and there is the inevitable development of resistance and subsequent disease progression.
APA, Harvard, Vancouver, ISO, and other styles
2

Toren, Paul. "Pre-clinical targeting of enzalutamide-resistant prostate cancer." Thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/60230.

Full text
Abstract:
Prostate cancer causes morbidity and mortality for thousands of Canadian men each year. Castration remains the primary treatment for recurrent or metastatic prostate cancer. However, castration is never curative, and the cancer inevitably recurs as castration resistant prostate cancer (CRPC). Newer androgen receptor (AR) antagonists such as enzalutamide(ENZ) demonstrate significant benefit in CRPC patients, but these agents remain non-curative. Therefore, the goal of this thesis was to explore novel strategies to target ENZ-resistant prostate cancer using previously developed models of resista
APA, Harvard, Vancouver, ISO, and other styles
3

Madeira, Leandro Roque. "Revisão sistemática entre abiraterona e enzalutamida no tratamento de pacientes com câncer de próstata metastático resistente à castração." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/17/17157/tde-23042018-105932/.

Full text
Abstract:
Introdução: O câncer de próstata metastático resistente à castração apresenta sobrevida inferior a 30% em cinco anos, e o único tratamento disponível para os pacientes até pouco tempo atrás era o docetaxel. Com o maior entendimento dos mecanismos de resistência desse câncer às terapias utilizadas, novas drogas foram desenvolvidas, entre elas a abiraterona, que atua no bloqueio da enzima 17-? desidrogenase-hidroxiesteroide e a enzalutamida que age diretamente nos receptores de androgênios. Foi realizada uma revisão sistemática dos estudos que avaliaram a eficácia e segurança da abiraterona mais
APA, Harvard, Vancouver, ISO, and other styles
4

Kim, Soojin. "Elucidation of AR impact on the paternally expressed Gene 10 (PEG10) in Enzalutamide-resistant prostate cancer." Thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/59301.

Full text
Abstract:
The full abstract for this thesis is available in the body of the thesis, and will be available when the embargo expires.<br>Medicine, Faculty of<br>Experimental Medicine, Division of<br>Medicine, Department of<br>Graduate
APA, Harvard, Vancouver, ISO, and other styles
5

Osbourne, Erica. "EPI-002 and enzalutamide combination therapy as a potential therapeutic benefit for castration-resistant prostate cancer patients." Thesis, University of British Columbia, 2014. http://hdl.handle.net/2429/50092.

Full text
Abstract:
Development of castration-resistant prostate cancer (CRPC) is thought to be dependent on androgen receptor (AR) transcriptional activity. Resistance to current therapies is linked to constitutively active AR splice variants that lack the ligand-binding domain (LBD). Metastatic tumours heterogeneously express varying levels of AR splice variants to full-length AR (fl-AR). AR splice variant V7 is frequently expressed and correlated with poor prognosis in patients. Since current therapies such as enzalutamide target the fl-AR LBD, which is absent in AR variants, an amino-terminal domain (NTD) inh
APA, Harvard, Vancouver, ISO, and other styles
6

(9452786), Elia G. Farah. "IDENTIFYING AND TARGETING PATHWAYS INVOLVED IN ENZALUTAMIDE-RESISTANT PROSTATE CANCER." Thesis, 2020.

Find full text
Abstract:
<p><a>Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is an FDA-approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-stage prostate cancer treatment.</a> After a short positive response period to enzalutamide, tumors will develop drug resistance. In these studies, we uncovered that NOTCH signaling and DNA methylation are a deregulated in enzalutamide-resistant cells. <i>NOTCH2</i> and<i> c-MYC </i><a>gene expression<i> </i>positively
APA, Harvard, Vancouver, ISO, and other styles
7

LI, JIA-SIN, and 李佳欣. "Effects of 3,3’-Diindolylmethane on enzalutamide-resistant prostate cancer cells." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/9s7m63.

Full text
Abstract:
碩士<br>輔仁大學<br>營養科學系碩士班<br>107<br>Prostate cancer is the second most common cancer in men, and about 50% of patients with prostate cancer were diagnosed in the late stage. The main option of clinical treatments for the late stage of prostate cancer is hormonal therapy. However, most patients have therapy-resistant and the rate of recurrence is high, and then develop to castration resistant prostate cancer (CRPC). In the treatment of CRPC, enzalutamide (ENZ) is one of the main drugs, which can inhibit androgen receptor (AR) signaling. Nevertheless, most patients had primary resistance to enzalut
APA, Harvard, Vancouver, ISO, and other styles
8

Lahcene, Halima. "Cancer de la prostate résistant à la castration métastatique : utilisation des nouveaux traitements dans un contexte réel au Québec." Thèse, 2017. http://hdl.handle.net/1866/19454.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Enzalutamide resistance"

1

Mukherji, Deborah, Aurelius Omlin, Carmel Pezaro, and Johann De Bono. Novel therapies and emerging strategies for the treatment of patients with castration-resistant prostate cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0069.

Full text
Abstract:
Castration-resistant prostate cancer (CRPC) represents a final stage of this malignancy for many men and is defined as the progression of prostate cancer despite castrate levels of testosterone. CRPC may present as a rising PSA, the development of new metastases, or worsening of known metastases. Recent advances have resulted in five new treatments for CRPC: the immunotherapy sipuleucel-T; the cytotoxic cabazitaxel; the androgen biosynthesis inhibitor abiraterone acetate; the radioisotope radium-223; and the antiandrogen enzalutamide. These have all improved overall survival in randomized phas
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Enzalutamide resistance"

1

Kimura, Go. "Enzalutamide Therapy for mCRPC in Japanese Men." In Hormone Therapy and Castration Resistance of Prostate Cancer. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-7013-6_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shevach, Jeffrey, Bridget K. Marcellino, William K. Oh, and Che-Kai Tsao. "Enzalutamide in Metastatic Castration Resistant Prostate Cancer." In Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31341-2_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zabell, Joseph. "Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy." In 50 Studies Every Urologist Should Know. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190655341.003.0018.

Full text
Abstract:
This chapter summarizes the findings of the landmark PREVAIL trial conducted in men with castrate-resistant prostate cancer who had received prior chemotherapy comparing enzalutamide to placebo. It demonstrated improved overall survival, radiographic progression-free survival, and time to cytotoxic chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Enzalutamide resistance"

1

Ketola, Kirsi, Jennifer Bishop, Martin Gleave, and Amina Zoubeidi. "Abstract C91: Targeting enzalutamide resistance in prostate cancer." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Basu, Hirak S., Cynthia L. Schrieber, Jamie M. Sperger, et al. "Abstract 2899: Mitophagy imparts enzalutamide resistance in prostate cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2899.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Steele, Thomas M., Maitreyee K. Jathal, Salma Siddiqui, and Paramita M. Ghosh. "Abstract 4676: Overcoming EGFR-induced resistance to enzalutamide in castration-resistant prostate cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Loriot, Yohann, Alexander Wyatt, Nader Al Nakouzi, et al. "Abstract 3386: Mechanisms of resistance to enzalutamide in LNCaP models." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Maxwell, Pamela J., Melanie McKechnie, Oisin Duddy, et al. "Abstract A087: Enzalutamide-induced hypoxia attenuates response and promotes resistance to enzalutamide in preclinical models of prostate cancer." In Abstracts: AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; December 2-5, 2017; Orlando, Florida. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.prca2017-a087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Verma, Shiv S., Eswar Shankar, Rajnee Kanwal, Ricky Chan, and Sanjay Gupta. "Abstract 1467: Metabolic reprogramming fuels prostate cancer cells towards enzalutamide resistance." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-1467.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

VELOT, Lauriane, Dominique Levesque, François-Michel Boisvert, Nicolas Bisson, and Frédéric Pouliot. "Abstract 220: Proteomic identification of therapeutics targets for Enzalutamide resistance in Castration Resistant Prostate Cancer." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kosoff, David, Jiaquan Yu, Vikram Suresh, David J. Beebe, and Joshua M. Lang. "Abstract 112: Tumor-associated macrophages promote enzalutamide resistance in microscale castrate-resistant prostate cancer models." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Steele, Thomas M., Maitreyee K. Jathal, Salma Siddiqui, et al. "Abstract 4842: Overcoming EGFR and ERK-mediated resistance to enzalutamide in castration-resistant prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4842.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Steele, Thomas M., Maitreyee K. Jathal, Salma Siddiqui, et al. "Abstract 4842: Overcoming EGFR and ERK-mediated resistance to enzalutamide in castration-resistant prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4842.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Enzalutamide resistance"

1

Szmulewitz, Russell. A Pharmacokinetic/Pharmacodynamic Study of the Glucocorticoid Receptor Antagonist Mifepristone Combined with Enzalutamide in Castrate-Resistant Prostate Cancer. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada613184.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Enzalutamide resistance' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography